

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE  
COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section  
13 or 15(d) of  
The Securities  
Exchange Act of  
1934**

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): **July 17, 2024**

---

**GILEAD SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**0-19731**  
(Commission File No.)

**94-3047598**  
(IRS Employer Identification  
No.)

**333 Lakeside Drive, Foster City, California**  
(Address of principal executive offices)

**94404**  
(Zip Code)

**650-574-3000**  
(Registrant's Telephone Number, Including Area Code)

---

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

		Name of each exchange on which registered
<b>Common Stock, par value, \$0.001 per share</b>	<b>GILD</b>	<b>The Nasdaq Global Select Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company “

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. “

---



---



---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 17, 2024, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that its Chief Medical Officer, Merdad V. Parsey, M.D., Ph.D., will leave the Company. No formal date has been established for Dr. Parsey’s transition. Dr. Parsey will continue in his role while the Company works to identify a successor and thereafter to assist with the transition of his duties, which is expected to occur through the first quarter of 2025 or such other date as mutually agreed.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

**Exhibit**

**Number    Description**

[99.1](#)            [Press Release by Gilead Sciences, Inc. dated July 17, 2024](#)

104            Cover Page Interactive Data File (embedded within the Inline XBRL document)

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GILEAD SCIENCES, INC.**  
(Registrant)

/s/ DEBORAH H. TELMAN

---

Deborah H. Telman  
EVP, Corporate Affairs, General Counsel and  
Corporate Secretary

Date: July 17, 2024

---